1.A Nine-Month-Old Boy With Isodicentric Chromosome 15: A Case Report.
Doug Ho PARK ; Seonggyu LIM ; Eun Sook PARK ; Eun Geol SIM
Annals of Rehabilitation Medicine 2013;37(2):291-294
Isodicentric chromosome 15 [idic(15)] is a rare chromosomal abnormality that occurs due to inverted duplication of chromosome 15q. It is associated with many clinical findings such as early central hypotonia, developmental delay, cognitive dysfunction, autism spectrum disorders, and seizure. Delayed development is a common problem referred to pediatric rehabilitation clinics. A 9-month-old boy with delayed development was referred to our clinic for assessment and treatment. On chromosomal analysis, he was diagnosed as idic(15) syndrome with 47,XY,+idic(15)(q12) on karyotyping. Herein we describe his clinical manifestations and provide a brief review of the related literature.
Aneuploidy
;
Child
;
Autism Spectrum Disorder
;
Chromosome Aberrations
;
Chromosomes, Human, Pair 15
;
Developmental Disabilities
;
Karyotyping
;
Muscle Hypotonia
;
Seizures
2.Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu BYEON ; Youjin KIM ; Sung Won LIM ; Jang Ho CHO ; Sehoon PARK ; Jiyun LEE ; Jong Mu SUN ; Yoon La CHOI ; Se Hoon LEE ; Jin Seok AHN ; Keunchil PARK ; Myung Ju AHN
Cancer Research and Treatment 2019;51(2):623-631
PURPOSE: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established. MATERIALS AND METHODS: Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy. RESULTS: Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progression-free survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response. CONCLUSION: The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to first- or second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.
Carcinoma, Non-Small-Cell Lung
;
Disease-Free Survival
;
Drug Therapy
;
Exons
;
Humans
;
Incidence
;
Korea
;
Mutagenesis, Insertional
;
Protein-Tyrosine Kinases
;
Receptor, Epidermal Growth Factor
;
Retrospective Studies
3.Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea.
Hee Kyung KIM ; Jun Soo HAM ; Seonggyu BYEON ; Kwai Han YOO ; Ki Sun JUNG ; Haa Na SONG ; Jinhyun CHO ; Ji Yun LEE ; Sung Hee LIM ; Hae Su KIM ; Ji Yeon KIM ; Jeong Eon LEE ; Seok Won KIM ; Seok Jin NAM ; Se Kyung LEE ; Soo Youn BAE ; Jin Seok AHN ; Young Hyuck IM ; Yeon Hee PARK
Cancer Research and Treatment 2016;48(4):1382-1388
PURPOSE: The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. MATERIALS AND METHODS: Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables. RESULTS: Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. CONCLUSION: Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.
Aged*
;
Breast Neoplasms*
;
Breast*
;
Follow-Up Studies
;
Humans
;
Korea*
;
Methods
;
Population Characteristics
;
Prevalence
;
Risk Factors
;
Survival Rate
;
Treatment Outcome